News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EPIRUS Biopharmaceuticals And Zalicus Inc. (ZLCS) Complete Merger - Combined Company Will Trade As EPIRUS Biopharmaceuticals


7/15/2014 10:46:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOSTON--(BUSINESS WIRE)--EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced today the completion of a merger with Zalicus Inc. (Zalicus, NASDAQ: ZLCS).

The combined company, which has been renamed EPIRUS Biopharmaceuticals, Inc., will focus on the business of EPIRUS and operate under the leadership of the EPIRUS management team, with Amit Munshi serving as the president and chief executive officer. The merger and name change became effective today. Beginning on July 16, 2014, EPIRUS will trade on NASDAQ under the symbol EPRS.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES